Literature DB >> 8234299

Molecular cloning and characterization of the human A3 adenosine receptor.

C A Salvatore1, M A Jacobson, H E Taylor, J Linden, R G Johnson.   

Abstract

The human A3 adenosine receptor was cloned from a striatal cDNA library using a probe derived from the homologous rat sequence. The cDNA encodes a protein of 318 amino acids and exhibits 72% and 85% overall identity with the rat and sheep A3 adenosine receptor sequences, respectively. Specific and saturable binding of the adenosine receptor agonist N6-(4-amino-3-[125I]iodobenzyl)adenosine [125I]ABA was measured on the human A3 receptor stably expressed in Chinese hamster ovary cells with a Kd = 10 nM. The potency order for adenosine receptor agonists was N-ethylcarboxamidoadenosine (NECA) > or = (R)-N6-phenyl-2-propyladenosine [(R)-PIA] > N6-cyclopentyladenosine (CPA) > (S)-N6-phenyl-2-propyladenosine [(S)-PIA]. The human receptor was blocked by xanthine antagonists, most potently by 3-(3-iodo-4-aminobenzyl)-8-(4-oxyacetate)phenyl-1-propylxanthine (I-ABOPX) with a potency order of I-ABOPX > 1,3-dipropyl-8-(4-acrylate)phenylxanthine > or = xanthine amino congener >> 1,3-dipropyl-8-cyclopentylxanthine. Adenosine, NECA, (R)- and (S)-PIA, and CPA inhibited forskolin-stimulated cAMP accumulation by 30-40% in stably transfected cells; I-ABA is a partial agonist. When measured in the presence of antagonists, the dose-response curves of NECA-induced inhibition of forskolin-stimulated cAMP accumulation were right-shifted. Antagonist potencies determined by Schild analyses correlated well with those established by competition for radioligand binding. The A3 adenosine receptor transcript is widespread and, in contrast to the A1, A2a, and A2b transcripts, the most abundant expression is found in the lung and liver. The tissue distribution of A3 mRNA is more similar to the widespread profile found in sheep than to the restricted profile found in the rat. This raises the possibility that numerous physiological effects of adenosine may be mediated by A3 adenosine receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8234299      PMCID: PMC47775          DOI: 10.1073/pnas.90.21.10365

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Drug antagonism and pAx.

Authors:  H O SCHILD
Journal:  Pharmacol Rev       Date:  1957-06       Impact factor: 25.468

2.  Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells.

Authors:  D van Calker; M Müller; B Hamprecht
Journal:  J Neurochem       Date:  1979-11       Impact factor: 5.372

3.  [125I]Aminobenzyladenosine, a new radioligand with improved specific binding to adenosine receptors in heart.

Authors:  J Linden; A Patel; S Sadek
Journal:  Circ Res       Date:  1985-02       Impact factor: 17.367

4.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

5.  A practical computer-based approach to the analysis of radioligand binding experiments.

Authors:  G A McPherson
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors.

Authors:  J Linden; A Patel; C Q Earl; R H Craig; S M Daluge
Journal:  J Med Chem       Date:  1988-04       Impact factor: 7.446

8.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.

Authors:  R F Bruns; G H Lu; T A Pugsley
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

9.  Adenosine-induced bronchoconstriction in asthma. Antagonism by inhaled theophylline.

Authors:  M J Cushley; A E Tattersfield; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1984-03

10.  Adenosine receptors in post-mortem human cerebral cortex and the effect of carbamazepine.

Authors:  P R Dodd; W E Watson; G A Johnston
Journal:  Clin Exp Pharmacol Physiol       Date:  1986-10       Impact factor: 2.557

View more
  92 in total

1.  Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release.

Authors:  C I Ezeamuzie; E Philips
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor.

Authors:  Zhan-Guo Gao; Aishe Chen; Dov Barak; Soo-Kyung Kim; Christa E Müller; Kenneth A Jacobson
Journal:  J Biol Chem       Date:  2002-03-12       Impact factor: 5.157

3.  A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.

Authors:  M L Trincavelli; D Tuscano; M Marroni; A Falleni; V Gremigni; S Ceruti; M P Abbracchio; K A Jacobson; F Cattabeni; C Martini
Journal:  Mol Pharmacol       Date:  2002-12       Impact factor: 4.436

Review 4.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

5.  Chapter 13. A3 Adenosine Receptors.

Authors:  Kenneth A Jacobson; Susanna Tchilibon; Bhalchandra V Joshi; Zhan-Guo Gao
Journal:  Annu Rep Med Chem       Date:  2003       Impact factor: 1.059

6.  Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.

Authors:  Amanda Ford; Annie Castonguay; Martin Cottet; Joshua W Little; Zhoumou Chen; Ashley M Symons-Liguori; Timothy Doyle; Terrance M Egan; Todd W Vanderah; Yves De Koninck; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 7.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

8.  Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety.

Authors:  Philippe Van Rompaey; Kenneth A Jacobson; Ariel S Gross; Zhan-Guo Gao; Serge Van Calenbergh
Journal:  Bioorg Med Chem       Date:  2005-02-15       Impact factor: 3.641

9.  Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives.

Authors:  H O Kim; X D Ji; N Melman; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1994-11-11       Impact factor: 7.446

10.  Species comparison of adenosine receptor subtypes in brain and testis.

Authors:  Gino Giannaccini; Laura Betti; Lionella Palego; Laura Fabbrini; Lara Schmid; Maura Castagna; Laura Giusti; Giovanni Mascia; Antonio Lucacchini
Journal:  Neurochem Res       Date:  2007-11-07       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.